Bioxytran and University of Minnesota Research Agreement

Bioxytran, Inc., a clinical-stage biotechnology company, announced a Sponsored Research Agreement with the University of Minnesota. This collaboration aims to support advanced biochemical research focused on understanding and developing novel polysaccharide and oligosaccharide interactions with biological targets. Dr. Kevin Mayo will direct the research at the University of Minnesota, leveraging its expertise in structural biology and nuclear magnetic resonance spectroscopy. The program, expected to run through early 2027, will explore carbohydrate-binding interactions to guide future therapeutic and diagnostic applications. Bioxytran will fund the research, and while the University of Minnesota retains intellectual property ownership, Bioxytran will have broad rights to use the resulting data for its internal research and development.